Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2504 (LINC02504)
- Target
- LINC02504
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic non-coding RNA, Other
01
Overview
Long intergenic non-protein coding RNA 2504 (LINC02504) is a human lncRNA transcript annotated as a non-coding RNA spanning more than 200 nucleotides and located in an intergenic region[1]. LINC02504 is implicated in transcriptional regulation and may act as an enhancer RNA in the activation of nearby genes, such as CPEB2, through epigenetic marks and enhancer loops[2]. Its expression is upregulated in several cancers and is associated with cell growth, proliferation, and migration in breast, colon, lung, and ovarian cancers[2]. Experimental silencing of LINC02504 leads to reduced cancer cell viability and colony formation in vitro, suggesting a possible oncogenic role. However, there are currently no approved therapeutics or interventions directly targeting this molecule, and its role is limited to basic research and as a potential cancer biomarker.
- Other names
- LINC02504long intergenic non-protein coding RNA 2504
02
Mechanism of action
Not established for any drug. Potential target mechanism involves indirect modulation via RNA interference or gene silencing (siRNA, shRNA)[2].
03
Biological functions
Regulation of gene expression[2]Possible regulation of enhancer activity and epigenetic modification[2]Potential involvement in cell proliferation, colony formation, cell migration, and cell viability in several cancer types (breast, colon, lung, ovarian)[2]
04
Disease associations
Cancer (evidence for roles in breast cancer, colon cancer, lung cancer, ovarian cancer)[2]Other (no strong evidence for non-cancer roles yet)
05
Safety considerations
Not established. As an RNA molecule mainly studied in basic research, no specific safety data are linked to targeting LINC02504.
06
Biomarkers
LINC02504 expression level has been proposed as a biomarker for prognosis in breast cancer (luminal A subtype) and other cancers (colon, lung, ovarian), but no validated companion diagnostics[2].
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2504 (LINC02504).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2504 (LINC02504).